Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7426)
All Articles published online
|
Publishing Process of This Article
|
May 14, 2015 (publication date) through Jul 12, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Israeli E, Zigmond E, Lalazar G, Klein A, Hemed N, Goldin E, Ilan Y. Oral mixture of autologous colon-extracted proteins for the Crohn’s disease: A double-blind trial. World J Gastroenterol 2015; 21(18): 5685-5694 [PMID: 25987796 DOI: 10.3748/wjg.v21.i18.5685] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i18/5685.htm |
| Number | Citing Articles |
| 1 |
Ariel Kenig, Tal Keidar-Haran, Henny Azmanov, Asa Kessler, Yotam Kolben, Tamar Tayri-Wilk, Nir Kalisman, Sarah Weksler-Zangen, Yaron Ilan. Low-Dose Colchicine Attenuates Sepsis-Induced Liver Injury: A Novel Method for Alleviating Systemic Inflammation. Inflammation 2023; 46(3): 963 doi: 10.1007/s10753-023-01783-9
|
| 2 |
Y. Ilan. Review article: novel methods for the treatment of non-alcoholic steatohepatitis - targeting the gut immune system to decrease the systemic inflammatory response without immune suppression. Alimentary Pharmacology & Therapeutics 2016; 44(11-12): 1168 doi: 10.1111/apt.13833
|
| 3 |
Tawfik Khoury, Dory Rotnemer-Golinkin, Lidya Zolotarev, Yaron Ilan. Orally administered anti-eotaxin-1 monoclonal antibody is biologically active in the gut and alleviates immune-mediated hepatitis: A novel anti-inflammatory personalized therapeutic approach. International Journal of Immunopathology and Pharmacology 2021; 35 doi: 10.1177/20587384211021215
|
| 4 |
Tahel Ilan-Ber, Yaron Ilan. The role of microtubules in the immune system and as potential targets for gut-based immunotherapy. Molecular Immunology 2019; 111: 73 doi: 10.1016/j.molimm.2019.04.014
|
| 5 |
Paolo Giuffrida, Sara Cococcia, Mariangela Delliponti, Marco Vincenzo Lenti, Antonio Di Sabatino. Controlling Gut Inflammation by Restoring Anti-Inflammatory Pathways in Inflammatory Bowel Disease. Cells 2019; 8(5): 397 doi: 10.3390/cells8050397
|
| 6 |
Satoshi Ino, Chikara Kohda, Kosuke Takeshima, Hiroki Ishikawa, Tomoko Norose, Toshiko Yamochi, Masafumi Takimoto, Hiroshi Takahashi, Kazuo Tanaka. Oral tolerance is inducible during active dextran sulfate sodium-induced colitis. World Journal of Gastrointestinal Pharmacology and Therapeutics 2016; 7(2): 242-253 doi: 10.4292/wjgpt.v7.i2.242
|
| 7 |
Ross John Porter, Caroline Andrews, Daniel Paul Brice, Scott Kenneth Durum, Mairi Hall McLean. Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?. Inflammatory Bowel Diseases 2018; 24(10): 2123 doi: 10.1093/ibd/izy230
|
| 8 |
Yaron Ilan. Microtubules as a potential platform for energy transfer in biological systems: a target for implementing individualized, dynamic variability patterns to improve organ function. Molecular and Cellular Biochemistry 2023; 478(2): 375 doi: 10.1007/s11010-022-04513-1
|
| 9 |
Yuval Ishay, Assaf Potruch, Asaf Schwartz, Marc Berg, Khurram Jamil, Samuel Agus, Yaron Ilan. A digital health platform for assisting the diagnosis and monitoring of COVID-19 progression: An adjuvant approach for augmenting the antiviral response and mitigating the immune-mediated target organ damage. Biomedicine & Pharmacotherapy 2021; 143: 112228 doi: 10.1016/j.biopha.2021.112228
|
| 10 |
Einat Almon, Tawfik Khoury, Ariel Drori, Svetlana Gingis-Velitski, Sari Alon, Raul Chertkoff, Mordechai Mushkat, Yoseph Shaaltiel, Yaron Ilan. An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy. Journal of Immunological Methods 2017; 446: 21 doi: 10.1016/j.jim.2017.03.023
|
| 11 |
Yaron Ilan. Oral immune therapy: targeting the systemic immune system via the gut immune system for the treatment of inflammatory bowel disease. Clinical & Translational Immunology 2016; 5(1) doi: 10.1038/cti.2015.47
|
| 12 |
Assaf Potruch, Asaf Schwartz, Yaron Ilan. The role of bacterial translocation in sepsis: a new target for therapy. Therapeutic Advances in Gastroenterology 2022; 15 doi: 10.1177/17562848221094214
|
| 13 |
Hajar Abbasi-Kenarsari, Neda Heidari, Kaveh Baghaei, Davar Amani, Mohammad Reza Zali, Sahar Gaffari Khaligh, Abbas Shafiee, Seyed Mahmoud Hashemi. Synergistic therapeutic effect of mesenchymal stem cells and tolerogenic dendritic cells in an acute colitis mouse model. International Immunopharmacology 2020; 88: 107006 doi: 10.1016/j.intimp.2020.107006
|